TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025.

PRNewsWire • 5 hours ago

TransMedics (TMDX) Beats Q4 Earnings and Revenue Estimates

TransMedics (TMDX) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.19 per share a year ago.

Zacks Investment Research • 4 minutes ago

Ahead of TransMedics (TMDX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

Zacks Investment Research • Feb 23, 2026

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 18, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 40,089 shares of its common stock and an aggregate of 26,549 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.

PRNewsWire • Feb 20, 2026

6 Stock Ideas for the Next 5 Years

In this podcast, Motley Fool co-founder and CEO Tom Gardner talks about separating AI contenders from pretenders, his two favorite market indicators, and lessons from the dot-com bubble. Plus, Tom shares six stock ideas for the next five years.

The Motley Fool • Feb 17, 2026

TransMedics to Present at Upcoming March Investor Conferences

ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.

PRNewsWire • Feb 17, 2026

TMDX Wins Full FDA IDE Approval for Next-Gen OCS ENHANCE Heart Trial

TransMedics secures full FDA IDE approval for its OCS ENHANCE Heart trial, clearing a key hurdle and advancing its push to expand heart transplant use.

Zacks Investment Research • Feb 16, 2026

TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026.

PRNewsWire • Feb 10, 2026

TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial

ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial.

PRNewsWire • Feb 9, 2026

TransMedics: Italian NOP Program Reinforces Huge International Opportunity

TransMedics: Italian NOP Program Reinforces Huge International Opportunity

Seeking Alpha • Feb 3, 2026